Hong Kong Pharmaceuticals Stock News

SEHK:2498
SEHK:2498Electronic

Assessing Robosense Technology (SEHK:2498) Valuation After First Profitable Quarter And Strong Robotics LiDAR Momentum

Robosense Technology (SEHK:2498) is back in focus after reporting its first profitable quarter, alongside full year 2025 results that showed higher sales, a smaller net loss, and strong momentum in robotics focused LiDAR shipments. See our latest analysis for Robosense Technology. Despite the earnings improvement, the recent 90 day share price return of a 4.86% decline and 1 year total shareholder return of an 8.37% decline suggest longer term momentum has been weak, with the first profitable...
SEHK:326
SEHK:326Entertainment

Assessing China Star Entertainment (SEHK:326) Valuation After Weak Full Year Earnings And Sharp Share Price Gains

Full year earnings spotlight China Star Entertainment (SEHK:326) drew investor attention after reporting full year 2025 results, with sales of HK$404.92 million and a net loss of HK$443.76 million, both weaker than the prior year. See our latest analysis for China Star Entertainment. Despite reporting weaker full year results, China Star Entertainment's recent momentum has been strong, with a 30 day share price return of 31.52% and a one year total shareholder return of 311.76%, suggesting...
SEHK:1585
SEHK:1585Auto

Yadea Group Holdings SEHK 1585 Net Margin Improvement Challenges Bearish Profitability Narratives

Yadea Group Holdings (SEHK:1585) opened FY 2025 with first half revenue of C¥19.2b and basic EPS of C¥0.54, setting the tone against a trailing twelve month picture that shows revenue at C¥37.0b and EPS at C¥0.96 on a net income base of C¥2.9b. Over the last three reported half year periods, revenue has moved from C¥14.4b in 1H 2024 to C¥13.8b in 2H 2024 and then to C¥19.2b in 1H 2025, while basic EPS shifted from C¥0.34 to C¥0.08 and then to C¥0.54, giving investors a clear read on how the...